Suzhou Ribo Life Science Co., Ltd. (HKG:6938)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
64.70
+0.35 (0.54%)
At close: Apr 2, 2026
Market Cap11.03B
Revenue (ttm)165.26M +4.1%
Net Income-309.43M
EPS-2.35
Shares Out170.55M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume154,000
Average Volume182,619
Open64.60
Previous Close64.35
Day's Range61.00 - 65.50
52-Week Range51.20 - 95.80
Betan/a
RSI58.06
Earnings DateMar 25, 2026

About Suzhou Ribo Life Science

Suzhou Ribo Life Science Co., Ltd. researches and develops small nucleic acid drugs for treating cardiovascular, metabolic, renal, liver, and other diseases. It develops RBD4059 for treating thrombotic diseases; RBD5044 for treating hypertrigly ceridemia; RBD7022 for treating Hypercho lesterolemia; RBD1016 for treating CHB and CHD that are in Phase II clinical trials. The company also develops RBD7007 and RBD2080 for treating renal diseases; and RBD1119 for treating thrombotic diseases, which are in Phase I clinical trials. In addition, it deve... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2007
Employees 404
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6938
Full Company Profile

Financial Performance

In 2025, Suzhou Ribo Life Science's revenue was 148.51 million, an increase of 4.12% compared to the previous year's 142.63 million. Losses were -278.06 million, 2.93% more than in 2024.

Financial numbers in CNY Financial Statements